 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- |||||| Axpaxli (intravitreal axitinib implant) / Ocular Therap
Enrollment open: Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - Feb 13, 2024
P3, N=300, Recruiting, Sponsor: Ocular Therapeutix, Inc.
Not yet recruiting --> Recruiting
- || Axpaxli (intravitreal axitinib implant) / Ocular Therap
Trial completion, Trial completion date: Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Jan 25, 2024
P1, N=21, Completed, Sponsor: Ocular Therapeutix, Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial completion date: Feb 2023 --> Dec 2023
- |||||||||| Axpaxli (intravitreal axitinib implant) / Ocular Therap
New P3 trial: Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - Jan 25, 2024
P3, N=300, Not yet recruiting, Sponsor: Ocular Therapeutix, Inc.
- || intravitreal axitinib implant (OTX-TKI) / Ocular Therap
Enrollment open, Trial completion date: Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (clinicaltrials.gov) - Feb 21, 2023
P1b, N=21, Recruiting, Sponsor: Ocular Therapeutix, Inc.
Active, not recruiting --> Completed | Trial completion date: Feb 2023 --> Dec 2023 Not yet recruiting --> Recruiting | Trial completion date: Jan 2024 --> Dec 2024
- || intravitreal axitinib implant (OTX-TKI) / Ocular Therap
New P1 trial: Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (clinicaltrials.gov) - Jan 25, 2023
P1b, N=21, Not yet recruiting, Sponsor: Ocular Therapeutix, Inc.
- | Axpaxli (intravitreal axitinib implant) / Ocular Therap
Trial primary completion date: Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Sep 6, 2022
P1, N=21, Active, not recruiting, Sponsor: Ocular Therapeutix, Inc.
Not yet recruiting --> Recruiting | Trial completion date: Jan 2024 --> Dec 2024 Trial primary completion date: Sep 2022 --> Feb 2023
- || Axpaxli (intravitreal axitinib implant) / Ocular Therap
Enrollment closed: CLN-0046: Treatment of AMD Subjects With OTX-TKI (clinicaltrials.gov) - Aug 3, 2022
P1, N=29, Active, not recruiting, Sponsor: Ocular Therapeutix, Inc.
Trial primary completion date: Sep 2022 --> Feb 2023 Recruiting --> Active, not recruiting
- intravitreal axitinib implant (OTX-TKI) / Ocular Therap
A Safety and Pharmacokinetic Study of a Novel Hydrogel-based Axitinib Intravitreal Implant (OTX-TKI) in Non-Human Primates (F0100) - Apr 29, 2022 - Abstract #ARVO2022ARVO_31;
OTX-TKI is currently being investigated in humans for the treatment of wet AMD in a U.S.-based Phase 1b clinical trial. Images:
- intravitreal axitinib implant (OTX-TKI) / Ocular Therap
A 6-Month GLP Toxicology Study of a Novel Hydrogel-based, Axitinib Intravitreal Implant (OTX-TKI) in Non-Human Primates (F0101) - Apr 29, 2022 - Abstract #ARVO2022ARVO_30;
No signs of intraocular inflammation or clinically significant changes in IOP and OCT images were observed. The safety and efficacy of OTX-TKI 600 µg intravitreal implant is currently being evaluated in humans for the treatment of wet age-related macular degeneration in a U.S.-based Phase 1b study.
- || Axpaxli (intravitreal axitinib implant) / Ocular Therap
Enrollment closed: Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Feb 6, 2022
P1, N=21, Active, not recruiting, Sponsor: Ocular Therapeutix, Inc.
The safety and efficacy of OTX-TKI 600 µg intravitreal implant is currently being evaluated in humans for the treatment of wet age-related macular degeneration in a U.S.-based Phase 1b study. Recruiting --> Active, not recruiting
- | Axpaxli (intravitreal axitinib implant) / Ocular Therap
Trial completion date, Trial primary completion date: CLN-0046: Treatment of AMD Subjects With OTX-TKI (clinicaltrials.gov) - Sep 21, 2021
P1, N=26, Recruiting, Sponsor: Ocular Therapeutix, Inc.
Recruiting --> Active, not recruiting Trial completion date: Nov 2021 --> Dec 2022 | Trial primary completion date: Nov 2021 --> Dec 2022
- || Axpaxli (intravitreal axitinib implant) / Ocular Therap
New P1 trial: Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Aug 3, 2021
P1, N=20, Recruiting, Sponsor: Ocular Therapeutix, Inc.
- intravitreal axitinib implant (OTX-TKI) / Ocular Therap
[VIRTUAL] Phase 1 Study of an Intravitreal Axitinib Hydrogel-based Implant for the Treatment of Neovascular Age- Related Macular Degeneration (nAMD) () - May 13, 2021 - Abstract #ARVO2021ARVO_2443;
Preliminary signs of biological activity, as evidenced by a decrease in CSFT in the 400 µg & 600 µg groups by two months, has been observed in many subjects with durability up to 13 months. Minimal movement & consistent resorption of implants has been observed.
- | Axpaxli (intravitreal axitinib implant) / Ocular Therap
Trial completion date, Trial primary completion date: CLN-0046: Treatment of AMD Subjects With OTX-TKI (clinicaltrials.gov) - May 27, 2020
P1, N=26, Recruiting, Sponsor: Ocular Therapeutix, Inc.
Minimal movement & consistent resorption of implants has been observed. Trial completion date: May 2020 --> Nov 2021 | Trial primary completion date: May 2020 --> Nov 2021
- | Axpaxli (intravitreal axitinib implant) / Ocular Therap
Enrollment change: CLN-0046: Treatment of AMD Subjects With OTX-TKI (clinicaltrials.gov) - Aug 8, 2019
P1, N=24, Recruiting, Sponsor: Ocular Therapeutix, Inc.
Trial completion date: May 2020 --> Nov 2021 | Trial primary completion date: May 2020 --> Nov 2021 N=18 --> 24
- || Axpaxli (intravitreal axitinib implant) / Ocular Therap
Enrollment open, Trial initiation date: CLN-0046: Treatment of AMD Subjects With OTX-TKI (clinicaltrials.gov) - Mar 22, 2019
P1, N=18, Recruiting, Sponsor: Ocular Therapeutix, Inc.
N=18 --> 24 Not yet recruiting --> Recruiting | Initiation date: Aug 2018 --> Feb 2019
- | Axpaxli (intravitreal axitinib implant) / Ocular Therap
New P1 trial: CLN-0046: Treatment of AMD Subjects With OTX-TKI (clinicaltrials.gov) - Aug 13, 2018
P1, N=25, Not yet recruiting, Sponsor: Ocular Therapeutix, Inc.